Presence of pleural effusion is associated with a poor prognosis in patients with epidermal growth factor receptor–mutated lung cancer receiving tyrosine kinase inhibitors as first-line treatment

Tso Fu Wang, Sung Chao Chu, Jen Jyh Lee, Gee Gwo Yang, Wei Han Huang, En Ting Chang, Tissot Low, Yi Feng Wu, Ruey Ho Kao, Chih Bin Lin

研究成果: 雜誌貢獻文章

4 引文 (Scopus)

摘要

Aim: This study was conducted to evaluate the effect of clinical factors on the treatment outcomes of lung cancer patients with active epidermal growth factor receptor (EGFR) mutations treated by first-line tyrosine kinase inhibitors (TKIs). Methods: Patients of stage IIIb or IV lung adenocarcinoma harboring mutated EGFR were enrolled between March 2010 and June 2014 and followed up until December 2015. The effects of various clinical features, such as age, sex, smoking history, EGFR mutation types, TKIs used, presence of pleural effusion, metastatic sites on progression-free survival (PFS) and overall survival (OS), were analyzed retrospectively. Results: A total of 104 patients were included in this study. Patients with pleural effusion at initial diagnosis had significantly shorter PFS and OS than those without pleural effusion (median PFS: 8.2 months vs 15.3 months, P = 0.0004; median OS: 16.3 months vs 28.2 months, P = 0.0003). Univariate analysis revealed that being male or a smoker was associated with short PFS, whereas smoking history, bony metastasis and malignant pleural effusion were associated with poor OS. Stepwise multivariate Cox regression analysis showed that the presence of pleural effusion and different TKI use were independent prognostic factors for PFS [hazard ratio [HR] = 2.50 (95% confidence interval [CI], 1.53–4.10), P = 0.0003 and HR = 0.55 (95% CI, 0.31–0.97), P = 0.0396, respectively], whereas the presence of pleural effusion and liver metastasis were associated with poor OS [HR = 2.79 (95% CI: 1.46–5.30), P = 0.0018 and HR = 2.12 (95% CI, 1.02–4.40), P = 0.0440, respectively]. Conclusion: The presence of pleural effusion predicts poor PFS and OS in lung adenocarcinoma patients receiving TKIs as the first-line treatment. Additional studies are warranted to elucidate the underlying mechanisms and determine novel strategies for improving the outcome of these patients.
原文英語
頁(從 - 到)304-313
頁數10
期刊Asia-Pacific Journal of Clinical Oncology
13
發行號4
DOIs
出版狀態已發佈 - 八月 1 2017
對外發佈Yes

指紋

Pleural Effusion
Epidermal Growth Factor
Protein-Tyrosine Kinases
Disease-Free Survival
Lung Neoplasms
Survival
Epidermal Growth Factor Receptor
Confidence Intervals
Therapeutics
Smoking
History
Neoplasm Metastasis
Malignant Pleural Effusion
Mutation
Regression Analysis
Liver

ASJC Scopus subject areas

  • Oncology

引用此文

Presence of pleural effusion is associated with a poor prognosis in patients with epidermal growth factor receptor–mutated lung cancer receiving tyrosine kinase inhibitors as first-line treatment. / Wang, Tso Fu; Chu, Sung Chao; Lee, Jen Jyh; Yang, Gee Gwo; Huang, Wei Han; Chang, En Ting; Low, Tissot; Wu, Yi Feng; Kao, Ruey Ho; Lin, Chih Bin.

於: Asia-Pacific Journal of Clinical Oncology, 卷 13, 編號 4, 01.08.2017, p. 304-313.

研究成果: 雜誌貢獻文章

Wang, Tso Fu ; Chu, Sung Chao ; Lee, Jen Jyh ; Yang, Gee Gwo ; Huang, Wei Han ; Chang, En Ting ; Low, Tissot ; Wu, Yi Feng ; Kao, Ruey Ho ; Lin, Chih Bin. / Presence of pleural effusion is associated with a poor prognosis in patients with epidermal growth factor receptor–mutated lung cancer receiving tyrosine kinase inhibitors as first-line treatment. 於: Asia-Pacific Journal of Clinical Oncology. 2017 ; 卷 13, 編號 4. 頁 304-313.
@article{c27e1f3674c349e6b4d3b598820450fc,
title = "Presence of pleural effusion is associated with a poor prognosis in patients with epidermal growth factor receptor–mutated lung cancer receiving tyrosine kinase inhibitors as first-line treatment",
abstract = "Aim: This study was conducted to evaluate the effect of clinical factors on the treatment outcomes of lung cancer patients with active epidermal growth factor receptor (EGFR) mutations treated by first-line tyrosine kinase inhibitors (TKIs). Methods: Patients of stage IIIb or IV lung adenocarcinoma harboring mutated EGFR were enrolled between March 2010 and June 2014 and followed up until December 2015. The effects of various clinical features, such as age, sex, smoking history, EGFR mutation types, TKIs used, presence of pleural effusion, metastatic sites on progression-free survival (PFS) and overall survival (OS), were analyzed retrospectively. Results: A total of 104 patients were included in this study. Patients with pleural effusion at initial diagnosis had significantly shorter PFS and OS than those without pleural effusion (median PFS: 8.2 months vs 15.3 months, P = 0.0004; median OS: 16.3 months vs 28.2 months, P = 0.0003). Univariate analysis revealed that being male or a smoker was associated with short PFS, whereas smoking history, bony metastasis and malignant pleural effusion were associated with poor OS. Stepwise multivariate Cox regression analysis showed that the presence of pleural effusion and different TKI use were independent prognostic factors for PFS [hazard ratio [HR] = 2.50 (95{\%} confidence interval [CI], 1.53–4.10), P = 0.0003 and HR = 0.55 (95{\%} CI, 0.31–0.97), P = 0.0396, respectively], whereas the presence of pleural effusion and liver metastasis were associated with poor OS [HR = 2.79 (95{\%} CI: 1.46–5.30), P = 0.0018 and HR = 2.12 (95{\%} CI, 1.02–4.40), P = 0.0440, respectively]. Conclusion: The presence of pleural effusion predicts poor PFS and OS in lung adenocarcinoma patients receiving TKIs as the first-line treatment. Additional studies are warranted to elucidate the underlying mechanisms and determine novel strategies for improving the outcome of these patients.",
keywords = "pleural effusion, prognosis, tyrosine kinase inhibitor",
author = "Wang, {Tso Fu} and Chu, {Sung Chao} and Lee, {Jen Jyh} and Yang, {Gee Gwo} and Huang, {Wei Han} and Chang, {En Ting} and Tissot Low and Wu, {Yi Feng} and Kao, {Ruey Ho} and Lin, {Chih Bin}",
year = "2017",
month = "8",
day = "1",
doi = "10.1111/ajco.12658",
language = "English",
volume = "13",
pages = "304--313",
journal = "Asia-Pacific Journal of Clinical Oncology",
issn = "1743-7555",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Presence of pleural effusion is associated with a poor prognosis in patients with epidermal growth factor receptor–mutated lung cancer receiving tyrosine kinase inhibitors as first-line treatment

AU - Wang, Tso Fu

AU - Chu, Sung Chao

AU - Lee, Jen Jyh

AU - Yang, Gee Gwo

AU - Huang, Wei Han

AU - Chang, En Ting

AU - Low, Tissot

AU - Wu, Yi Feng

AU - Kao, Ruey Ho

AU - Lin, Chih Bin

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Aim: This study was conducted to evaluate the effect of clinical factors on the treatment outcomes of lung cancer patients with active epidermal growth factor receptor (EGFR) mutations treated by first-line tyrosine kinase inhibitors (TKIs). Methods: Patients of stage IIIb or IV lung adenocarcinoma harboring mutated EGFR were enrolled between March 2010 and June 2014 and followed up until December 2015. The effects of various clinical features, such as age, sex, smoking history, EGFR mutation types, TKIs used, presence of pleural effusion, metastatic sites on progression-free survival (PFS) and overall survival (OS), were analyzed retrospectively. Results: A total of 104 patients were included in this study. Patients with pleural effusion at initial diagnosis had significantly shorter PFS and OS than those without pleural effusion (median PFS: 8.2 months vs 15.3 months, P = 0.0004; median OS: 16.3 months vs 28.2 months, P = 0.0003). Univariate analysis revealed that being male or a smoker was associated with short PFS, whereas smoking history, bony metastasis and malignant pleural effusion were associated with poor OS. Stepwise multivariate Cox regression analysis showed that the presence of pleural effusion and different TKI use were independent prognostic factors for PFS [hazard ratio [HR] = 2.50 (95% confidence interval [CI], 1.53–4.10), P = 0.0003 and HR = 0.55 (95% CI, 0.31–0.97), P = 0.0396, respectively], whereas the presence of pleural effusion and liver metastasis were associated with poor OS [HR = 2.79 (95% CI: 1.46–5.30), P = 0.0018 and HR = 2.12 (95% CI, 1.02–4.40), P = 0.0440, respectively]. Conclusion: The presence of pleural effusion predicts poor PFS and OS in lung adenocarcinoma patients receiving TKIs as the first-line treatment. Additional studies are warranted to elucidate the underlying mechanisms and determine novel strategies for improving the outcome of these patients.

AB - Aim: This study was conducted to evaluate the effect of clinical factors on the treatment outcomes of lung cancer patients with active epidermal growth factor receptor (EGFR) mutations treated by first-line tyrosine kinase inhibitors (TKIs). Methods: Patients of stage IIIb or IV lung adenocarcinoma harboring mutated EGFR were enrolled between March 2010 and June 2014 and followed up until December 2015. The effects of various clinical features, such as age, sex, smoking history, EGFR mutation types, TKIs used, presence of pleural effusion, metastatic sites on progression-free survival (PFS) and overall survival (OS), were analyzed retrospectively. Results: A total of 104 patients were included in this study. Patients with pleural effusion at initial diagnosis had significantly shorter PFS and OS than those without pleural effusion (median PFS: 8.2 months vs 15.3 months, P = 0.0004; median OS: 16.3 months vs 28.2 months, P = 0.0003). Univariate analysis revealed that being male or a smoker was associated with short PFS, whereas smoking history, bony metastasis and malignant pleural effusion were associated with poor OS. Stepwise multivariate Cox regression analysis showed that the presence of pleural effusion and different TKI use were independent prognostic factors for PFS [hazard ratio [HR] = 2.50 (95% confidence interval [CI], 1.53–4.10), P = 0.0003 and HR = 0.55 (95% CI, 0.31–0.97), P = 0.0396, respectively], whereas the presence of pleural effusion and liver metastasis were associated with poor OS [HR = 2.79 (95% CI: 1.46–5.30), P = 0.0018 and HR = 2.12 (95% CI, 1.02–4.40), P = 0.0440, respectively]. Conclusion: The presence of pleural effusion predicts poor PFS and OS in lung adenocarcinoma patients receiving TKIs as the first-line treatment. Additional studies are warranted to elucidate the underlying mechanisms and determine novel strategies for improving the outcome of these patients.

KW - pleural effusion

KW - prognosis

KW - tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85025833902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85025833902&partnerID=8YFLogxK

U2 - 10.1111/ajco.12658

DO - 10.1111/ajco.12658

M3 - Article

VL - 13

SP - 304

EP - 313

JO - Asia-Pacific Journal of Clinical Oncology

JF - Asia-Pacific Journal of Clinical Oncology

SN - 1743-7555

IS - 4

ER -